Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,585.60
(
-0.57%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
104.50
(
0.06%
)
Bitcoin
70,601.42
(
1.01%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dav1234 post# 172589

Monday, 01/13/2014 2:17:59 PM

Monday, January 13, 2014 2:17:59 PM

Post# of 257262
PTLA—Despite having Andexanet Alfa* collaborations with all participants in the FXa market, no one has apparently made a move to acquire the company and thereby obtain a competitive advnatge in the oral-anticoagulation market. This omission (IMO) speaks to the low value suitors are ascribing to PTLA’s Betrixaban program.

*F/k/a PRT-4445.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today